Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement

Infection and Immunity

Volumn 83, Issue 3, 2015, Pages 1056-1067

  Putrinš, Marta ^a   Kogermann, Karin ^a   Lukk, Eliisa ^a   Lippus, Markus ^a   Varik, Vallo ^a   Tenson, Tanel ^a  

^a UNIVERSITY OF TARTU   (Estonia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; COMPLEMENT COMPONENT C3B; NORFLOXACIN; ANTIINFECTIVE AGENT; COMPLEMENT COMPONENT C3;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL DIVISION; CELL GROWTH; CELL SUBPOPULATION; CELL SURVIVAL; COLONY FORMING UNIT; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOLYSIS; FLOW CYTOMETRY; GENETIC HETEROGENEITY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; UROPATHOGENIC ESCHERICHIA COLI; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; ULTRASTRUCTURE;

AMIKACIN; AMPICILLIN; ANTI-BACTERIAL AGENTS; COMPLEMENT C3; DRUG RESISTANCE, BACTERIAL; GENETIC HETEROGENEITY; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, FLUORESCENCE; NORFLOXACIN; PHENOTYPE; UROPATHOGENIC ESCHERICHIA COLI;

EID: 84923010685     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02725-14     Document Type: Article

References (56)

1. Young D, Hussell T, Dougan G. 2002. Chronic bacterial infections: living with unwanted guests. Nat Immunol 3:1026-1032. http://dx.doi.org/10.1038/ni1102-1026.
2. Sarma JV, Ward PA. 2011. The complement system. Cell Tissue Res 343:227-235. http://dx.doi.org/10.1007/s00441-010-1034-0.
3. Timar KK, Dallos A, Kiss M, Husz S, Bos JD, Asghar SS. 2007. Expression of terminal complement components by human keratinocytes. Mol Immunol 44:2578-2586. http://dx.doi.org/10.1016/j.molimm.2006.12.014.
4. Liu YF, Yan JJ, Lei HY, Teng CH, Wang MC, Tseng CC, Wu JJ. 2012. Loss of outer membrane protein C in Escherichia coli contributes to both antibiotic resistance and escaping antibody-dependent bactericidal activity. Infect Immun 80:1815-1822. http://dx.doi.org/10.1128/IAI.06395-11.
5. Merino S, Tomas J. 2010. Bacterial capsules and evasion ofimmuneresponses. In Encyclopedia of life sciences. John Wiley & Sons, Ltd., Chichester, United Kingdom. http://dx.doi.org/10.1002/9780470015902.a0000957.pub3.
6. Buckles EL, Wang X, Lane MC, Lockatell CV, Johnson DE, Rasko DA, Mobley HL, Donnenberg MS. 2009. Role of the K2 capsule in Escherichia coli urinary tract infection and serum resistance. J Infect Dis 199:1689-1697. http://dx.doi.org/10.1086/598524.
7. Miajlovic H, Smith SG. 2014. Bacterial self-defense: how Escherichia coli evades serum killing. FEMS Microbiol Lett 354:1-9. http://dx.doi.org/10.1111/1574-6968.12419.
8. Miajlovic H, Cooke NM, Moran GP, Rogers TR, Smith SG. 2014. Response of extraintestinal pathogenic Escherichia coli to human serum reveals a protective role for Rcs-regulated exopolysaccharide colanic acid. Infect Immun 82:298-305. http://dx.doi.org/10.1128/IAI.00800-13.
9. Sarkar S, Ulett GC, Totsika M, Phan MD, Schembri MA. 2014. Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli. PLoS One 9:e94786. http://dx.doi.org/10.1371/journal.pone.0094786.
10. Matsuura M. 2013. Structural modifications of bacterial lipopolysaccharide that facilitate gram-negative bacteria evasion of host innate immunity. Front Immunol 4:109. http://dx.doi.org/10.3389/fimmu.2013.00109.
11. Davis SD, Wedgwood RJ. 1965. Kinetics of the bactericidal action of normal serum on gram-negative bacteria. J Immunol 95:75-79.
12. Rowley D, Wardlaw AC. 1958. Lysis of gram-negative bacteria by serum. J Gen Microbiol 18:529-533. http://dx.doi.org/10.1099/00221287-18-2-529.
13. DeMatteo CS, Hammer MC, Baltch AL, Smith RP, Sutphen NT, Michelsen PB. 1981. Susceptibility of Pseudomonas aeruginosa to serum bactericidal activity. A comparison of three methods with clinical correlations. J Lab Clin Med 98:511-518.
14. Tee GL, Scott GK. 1980. Analysis of outer membrane components of Escherichia coli ML308 225 and of a serum-resistant mutant. Infect Immun 28:387-392.
15. Wooster DG, Maruvada R, Blom AM, Prasadarao NV. 2006. Logarithmic phase Escherichia coli K1 efficiently avoids serum killing by promoting C4bp-mediated C3b and C4b degradation. Immunology 117:482-493. http://dx.doi.org/10.1111/j.1365-2567.2006.02323.x.
16. Biedzka-Sarek M, Venho R, Skurnik M. 2005. Role of YadA, Ail, and lipopolysaccharide in serum resistance of Yersinia enterocolitica serotype O:3. Infect Immun 73:2232-2244. http://dx.doi.org/10.1128/IAI.73.4.2232-2244.2005.
17. Dalia AB, Weiser JN. 2011. Minimization of bacterial size allows for complement evasion and is overcome by the agglutinating effect of antibody. Cell Host Microbe 10:486-496. http://dx.doi.org/10.1016/j.chom.2011.09.009.
18. Blango MG, Mulvey MA. 2010. Persistence of uropathogenic Escherichia coli in the face of multiple antibiotics. Antimicrob Agents Chemother 54:1855-1863. http://dx.doi.org/10.1128/AAC.00014-10.
19. Lewis K. 2005. Persister cells and the riddle of biofilm survival. Biochemistry 70:267-274. http://dx.doi.org/10.1007/s10541-005-0111-6.
20. Mulcahy LR, Burns JL, Lory S, Lewis K. 2010. Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis. J Bacteriol 192:6191-6199. http://dx.doi.org/10.1128/JB.01651-09.
21. Lafleur MD, Qi Q, Lewis K. 2010. Patients with long-term oral carriage harbor high-persister mutants of Candida albicans. Antimicrob Agents Chemother 54:39-44. http://dx.doi.org/10.1128/AAC.00860-09.
22. Skjot-Rasmussen L, Hammerum AM, Jakobsen L, Lester CH, Larsen P, Frimodt-Moller N. 2011. Persisting clones of Escherichia coli isolates from recurrent urinary tract infection in men and women. J Med Microbiol 60:550-554. http://dx.doi.org/10.1099/jmm.0.026963-0.
23. Rosen DA, Hooton TM, Stamm WE, Humphrey PA, Hultgren SJ. 2007. Detection of intracellular bacterial communities in human urinary tract infection. PLoS Med 4:e329. http://dx.doi.org/10.1371/journal.pmed.0040329.
24. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107-131. http://dx.doi.org/10.1007/978-3-540-75418-3_6.
25. Mobley HL, Green DM, Trifillis AL, Johnson DE, Chippendale GR, Lockatell CV, Jones BD, Warren JW. 1990. Pyelonephritogenic Escherichia coli and killing of cultured human renal proximal tubular epithelial cells: role of hemolysin in some strains. Infect Immun 58:1281-1289.
26. Datsenko KA, Wanner BL. 2000. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci USA 97:6640-6645. http://dx.doi.org/10.1073/pnas.120163297.
27. Vimberg V, Tats A, Remm M, Tenson T. 2007. Translation initiation region sequence preferences in Escherichia coli. BMC Mol Biol 8:100. http://dx.doi.org/10.1186/1471-2199-8-100.
28. Andrews JM. 2001. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 48(Suppl 1):S5-S16. http://dx.doi.org/10.1093/jac/48.suppl_1.5.
29. Kamentsky L, Jones TR, Fraser A, Bray MA, Logan DJ, Madden KL, Ljosa V, Rueden C, Eliceiri KW, Carpenter AE. 2011. Improved structure, function and compatibility for CellProfiler: modular highthroughput image analysis software. Bioinformatics 27:1179-1180. http://dx.doi.org/10.1093/bioinformatics/btr095.
30. Welch RA, Burland V, Plunkett G, III, Redford P, Roesch P, Rasko D, Buckles EL, Liou SR, Boutin A, Hackett J, Stroud D, Mayhew GF, Rose DJ, Zhou S, Schwartz DC, Perna NT, Mobley HL, Donnenberg MS, Blattner FR. 2002. Extensive mosaic structure revealed by the complete genome sequence of uropathogenic Escherichia coli. Proc Natl Acad Sci USA 99:17020-17024. http://dx.doi.org/10.1073/pnas.252529799.
31. Debnath I, Norton JP, Barber AE, Ott EM, Dhakal BK, Kulesus RR, Mulvey MA. 2013. The Cpx stress response system potentiates the fitness and virulence of uropathogenic Escherichia coli. Infect Immun 81:1450-1459. http://dx.doi.org/10.1128/IAI.01213-12.
32. Diard M, Baeriswyl S, Clermont O, Gouriou S, Picard B, Taddei F, Denamur E, Matic I. 2007. Caenorhabditis elegans as a simple model to study phenotypic and genetic virulence determinants of extraintestinal pathogenic Escherichia coli. Microbes Infect 9:214-223. http://dx.doi.org/10.1016/j.micinf.2006.11.009.
33. Kilpi MK, Atosuo JT, Lilius EM. 2009. Bacteriolytic activity of the alternative pathway of complement differs kinetically from the classical pathway. Dev Comp Immunol 33:1102-1110. http://dx.doi.org/10.1016/j.dci.2009.06.007.
34. Bigger J. 1944. Treatment of staphylococcal infections with penicillin by intermittent sterilisation. Lancet 244:497-500. http://dx.doi.org/10.1016/S0140-6736(00)74210-3.
35. Moyed HS, Bertrand KP. 1983. hipA, a newly recognized gene of Escherichia coli K-12 that affects frequency of persistence after inhibition of murein synthesis. J Bacteriol 155:768-775.
36. Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622-1625. http://dx.doi.org/10.1126/science.1099390.
37. Keren I, Shah D, Spoering A, Kaldalu N, Lewis K. 2004. Specialized persister cells and the mechanism of multidrug tolerance in Escherichia coli. J Bacteriol 186:8172-8180. http://dx.doi.org/10.1128/JB.186.24.8172-8180.2004.
38. Allison KR, Brynildsen MP, Collins JJ. 2011. Metabolite-enabled eradication of bacterial persisters by aminoglycosides. Nature 473:216-220. http://dx.doi.org/10.1038/nature10069.
39. Jõers A, Kaldalu N, Tenson T. 2010. The frequency of persisters in Escherichia coli reflects the kinetics of awakening from dormancy. J Bacteriol 192:3379-3384. http://dx.doi.org/10.1128/JB.00056-10.
40. Roostalu J, Joers A, Luidalepp H, Kaldalu N, Tenson T. 2008. Cell division in Escherichia coli cultures monitored at single cell resolution. BMC Microbiol 8:68. http://dx.doi.org/10.1186/1471-2180-8-68.
41. Orman MA, Brynildsen MP. 2013. Dormancy is not necessary or sufficient for bacterial persistence. Antimicrob Agents Chemother 57:3230-3239. http://dx.doi.org/10.1128/AAC.00243-13.
42. Acar M, Mettetal JT, van Oudenaarden A. 2008. Stochastic switching as a survival strategy in fluctuating environments. Nat Genet 40:471-475. http://dx.doi.org/10.1038/ng.110.
43. Geisel N, Vilar JM, Rubi JM. 2011. Optimal resting-growth strategies of microbial populations in fluctuating environments. PLoS One 6:e18622. http://dx.doi.org/10.1371/journal.pone.0018622.
44. Shah D, Zhang Z, Khodursky A, Kaldalu N, Kurg K, Lewis K. 2006. Persisters: a distinct physiological state of E. coli. BMC Microbiol 6:53. http://dx.doi.org/10.1186/1471-2180-6-53.
45. Reimer LG, Wilson ML, Weinstein MP. 1997. Update on detection of bacteremia and fungemia. Clin Microbiol Rev 10:444-465.
46. Clarke DJ. 2010. The Rcs phosphorelay: more than just a two-component pathway. Future Microbiol 5:1173-1184. http://dx.doi.org/10.2217/fmb.10.83.
47. Lewis K. 2010. Persister cells. Annu Rev Microbiol 64:357-372. http://dx.doi.org/10.1146/annurev.micro.112408.134306.
48. Li K, Zhou W, Hong Y, Sacks SH, Sheerin NS. 2009. Synergy between type 1 fimbriae expression and C3 opsonisation increases internalisation of Escherichia coli by human tubular epithelial cells. BMC Microbiol 9:64. http://dx.doi.org/10.1186/1471-2180-9-64.
49. Bokil NJ, Totsika M, Carey AJ, Stacey KJ, Hancock V, Saunders BM, Ravasi T, Ulett GC, Schembri MA, Sweet MJ. 2011. Intramacrophage survival of uropathogenic Escherichia coli: differences between diverse clinical isolates and between mouse and human macrophages. Immunobiology 216:1164-1171. http://dx.doi.org/10.1016/j.imbio.2011.05.011.
50. Sturm A, Heinemann M, Arnoldini M, Benecke A, Ackermann M, Benz M, Dormann J, Hardt WD. 2011. The cost of virulence: retarded growth of Salmonella typhimurium cells expressing type III secretion system 1. PLoS Pathog 7:e1002143. http://dx.doi.org/10.1371/journal.ppat.1002143.
51. Martinez-Ramos I, Mulet X, Moya B, Barbier M, Oliver A, Alberti S. 2014. Overexpression of MexCD-OprJ reduces Pseudomonas aeruginosa virulence by increasing its susceptibility to complement-mediated killing. Antimicrob Agents Chemother 58:2426-2429. http://dx.doi.org/10.1128/AAC.02012-13.
52. Blanchard C, Barnett P, Perlmutter J, Dunman PM. 2014. Identification of Acinetobacter baumannii serum-associated antibiotic efflux pump inhibitors. Antimicrob Agents Chemother 58:6360-6370. http://dx.doi.org/10.1128/AAC.03535-14.
53. Fukuoka T, Ohya S, Narita T, Katsuta M, Iijima M, Masuda N, Yasuda H, Trias J, Nikaido H. 1993. Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob Agents Chemother 37:322-327. http://dx.doi.org/10.1128/AAC.37.2.322.
54. Skurnik D, Roux D, Cattoir V, Danilchanka O, Lu X, Yoder-Himes DR, Han K, Guillard T, Jiang D, Gaultier C, Guerin F, Aschard H, Leclercq R, Mekalanos JJ, Lory S, Pier GB. 2014. Enhanced in vivo fitness of carbapenem-resistant oprD mutants of Pseudomonas aeruginosa revealed through high-throughput sequencing. Proc Natl Acad Sci USA 110: 20747-20752. http://dx.doi.org/10.1073/pnas.1221552110.
55. Helaine S, Cheverton AM, Watson KG, Faure LM, Matthews SA, Holden DW. 2014. Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science 343:204-208. http://dx.doi.org/10.1126/science.1244705.
56. Claudi B, Sprote P, Chirkova A, Personnic N, Zankl J, Schurmann N, Schmidt A, Bumann D. 2014. Phenotypic variation of salmonella in host tissues delays eradication by antimicrobial chemotherapy. Cell 158:722-733. http://dx.doi.org/10.1016/j.cell.2014.06.045.